The invention relates to a method for improving angiogenic potential of a mesenchymal stem cell (MSC), the method comprising culturing the MSC on a substrate having stiffness of about 1 kPa to 100 kPa and coated with a matrix protein, wherein the MSC has improved angiogenic potential when compared with a MSC cultured under identical conditions except not cultured on a substrate having stiffness of about 1 kPa to 100 kPa and not coated with a matrix protein. The invention also relates to a MSC having angiogenic potential when improved by the method, and to therapeutic use of the improved MSC for treating coronary artery disease (CAD) or peripheral artery disease (PAD) in a subject having CAD or PAD.

Described herein are mesenchymal stem cells (MCS) expressing hybrid allosteric receptors (HAR) that are responsive to stromal cell-derived factor 1 alpha (SDF-1α) secreted from acutely infarcted myocardium. Binding of SDF-1α to CXCR4 activates the co-stimulatory signals, bone morphogenetic protein 2 type II receptor (BMP2R2) and BMP type I receptor (ALK3), in order to accelerate the differentiation into cardiomyocytes. HAR-MSC CXCR4 differentiates into cardiomyocytes through Smad1/5 phosphorylation induced by the BMP2 signaling. In acute myocardial infarction (AMI) models, HAR-MSC CXCR4 treatment leads to the functional improvements by facilitated differentiation and increased cytokine secretion. HAR-MSC CXCR4 cells can be used for the treatment of AMI.

The present invention relates to the discovery that different stem cell types (e.g., bone marrow-derived mesenchymal stem cells (RM-MSC) and adipose-derived mesenchymal stem cells (AT-MSC)) undergo large changes in lung epithelial marker 5 expression depending on the substrate on which they are cultured. The present invention includes methods and compositions for differentiating of mesenchymal stem cells, such as bone marrow and adipose tissue mesenchymal stem cells, into lung cells, populations of lung cells, and methods of alleviating or treating a lung defect in a subject in need thereof.

The present invention belongs to the field of biomedicine, and relates to an inducer for inducing a mesenchymal stem cell to differentiate into an islet cell. An inducer for inducing a mesenchymal stem cell to differentiate into an islet cell consisted of the following components: GLP-1, parathyroid hormone, paracetamol, rapamycin, icariin, trametinib, EPO and VEGF. Each component in a inducer for inducing a mesenchymal stem cell to differentiate into an islet cell of the present invention is safe and non-toxic, requiring fewer steps and short time to induce differentiation, with high induction efficiency.

Disclosed are a medium for differentiating neural stem cells into oligodendrocyte precursors and a method for preparing oligodendrocyte precursors by using the medium. The medium does not contain exogenous factors, and can avoid the contamination of exogenous factors and differentiate oligodendrocyte precursors.

An isolated human cell is disclosed comprising at least one mesenchymal stem cell phenotype and secreting brain-derived neurotrophic factor (BDNF), wherein a basal secretion of the BDNF is at least five times greater than a basal secretion of the BDNF in a mesenchymal stem cell. Methods of generating same and uses of same are also disclosed.

A method of generating MSCs which secrete neurotrophic factors (NTFs) comprising incubating a population of undifferentiated mesenchymal stem cells (MSCs) in a differentiating medium comprising basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), heregulin and cAMP.

The present invention relates to an apicidin composition for inducing differentiation of mesenchymal stem cells into cardiac-committed cells, and a method for inducing differentiation into cardiac-committed cells using the same. The present invention allows mesenchymal stem cells to be specifically induced to differentiate into cardiac-committed cells even when an apicidin is treated for only a very short period of time of 24 hours, thereby being capable of solving the extremely low cardiomyogenic differentiation efficiency of mesenchymal stem cells, high cost, and long-term problems in the conventional art, and thus the present invention can be usefully used for treating heart disease.

The present invention relates to anticancer extracellular vesicles, a preparation method therefor, and an anticancer composition comprising same. Immune-tolerized extracellular vesicles containing LDHB and PGC-1α of the present invention provide cancer treatment, suppression of cancer metastasis, and cancer prevention technologies by normalizing cancer cell-specific aerobic glycolysis energy metabolic pathway in which lactate and hydrogen ions, which form a tumor microenvironment favorable for immune evasion, proliferation, metastasis and invasion of cancer cells, are produced, thereby enabling tumors to be effectively removed by means of the immune system of a patient.

The invention provides methods, compositions, uses and kits relating to exosomes isolated from progenitor cells.